Clinical Microbiology Market Size, Share & Trends by Application (Pharma, Food, Clinical,Manufacturing, Environment), Disease (Respiratory Disease, Blood Stream, GIT, UTI), Product (Instrument, Analyzer, Reagent), End User, and Region - Global Forecast to 2029
The Clinical microbiology market is projected to reach USD 6.9 billion by 2029 from USD 5.0 billion in 2024 with a CAGR of 6.5% during the forecast period. The clinical microbiology market is experiencing significant growth driven by recent technological advancements in disease diagnostics, such as rapid molecular testing and laboratory automation, aiding faster and more precise detection of infectious agents. Additionally, the rising global incidence of infectious diseases due to population growth, urbanization, and international travel is driving demand for advanced microbiology testing solutions. However, challenges including limited reimbursement policies for microbiology testing procedures and operational barriers like the need for skilled personnel and complex regulatory frameworks pose obstacles to market expansion, particularly in resource-constrained settings. Addressing these challenges will be crucial to improving accessibility and affordability of microbiology testing services worldwide.
“The Instruments segment accounted for a substantial share of the clinical microbiology market, by type in 2023.”
The instruments segment is projected to dominate the clinical microbiology industry throughout the forecast period. This segment's substantial market share can be attributed to several factors. Firstly, there is significant adoption of conventional laboratory instruments by researchers and academia, with a notable increase in industry-academia collaborations focused on genomic research. Secondly, advancements in molecular techniques and proteomics, including innovations such as integrating microfluidics with PCR and applying nanotechnology to qPCR techniques, are driving the segment's growth. Lastly, the ongoing trend of laboratory automation among clinical laboratories is contributing to the expansion and prominence of the instruments segment within the clinical microbiology industry.
“ By Application Pharmaceutical Application segment accounted for the largest share in the healthcare clinical microbiology market.”
The pharmaceuticals segment represents the largest application area within the clinical microbiology industry and is expected to maintain its dominance throughout the forecast period. This significant share can be primarily attributed to the presence of well-established and widely accepted regulations governing microbial contamination evaluation during pharmaceutical manufacturing and raw material procurement. Regulatory bodies such as the WHO, FDA, MHRA (UK), European Medicines Agency (EU), TGA (Australia), and ANVISA (Brazil) have defined stringent guidelines for assessing microbial contamination in excipients and active pharmaceutical ingredients (APIs) to ensure sterile drug manufacturing and microbial load testing of finished pharmaceutical products. Moreover, pharmaceutical manufacturing processes are rigorously monitored and controlled according to various pharmacopeias on a global scale. The increasing production volume of pharmaceutical drugs worldwide also contributes significantly to the growth of this application segment.
“North America to witness the substantial growth rate during the forecast period.”
North America, which includes the United States and Canada, holds a leading position in the clinical microbiology market. This region is characterized by its maturity, marked by widespread use of clinical microbiology technologies among key end-users such as hospitals, research laboratories, diagnostic centers, and commercial service providers. Additionally, North America benefits from well-established distribution channels for manufacturers and suppliers of clinical microbiology products. The region's growth is propelled by factors including easy accessibility to and high adoption of advanced diagnostic technologies, supported by substantial per capita healthcare expenditure by the US and Canadian governments annually, along with favorable government regulations that foster industry development.
The break-down of primary participants is as mentioned below:
The prominent players in the global healthcare clinical microbiology market include BioMйrieux (France), Danaher Corporation (US), Becton, Dickinson, and Company (BD) (US), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Bruker (US), Hologic, Inc. (US), Merck KGaA(Germany), Bio-Rad Laboratories, Inc.(US), QIAGEN(Netherlands), Shimadzu Corporation(Japan), Neogen Corporation (US), Siemens Healthineers AG (Germany). With Emerging players including, Hardy Diagnostics (US), EMSL Analytical, Inc. (US), Lofilchem S.R.L (Italy), TCS Biosciences (UK), Cole-Parmer Instrument Company, LLC (US), Memmert GmbH + Co.KG (Germany), Vacutest Kima S.r.l (Germany), Rapid Micro Biosystems, Inc. (US), Biotechnology Solutions TX, LLC (US), and Arrow Diagnostics Srl (Italy).
Research Coverage:
The report analyzes the Clinical microbiology market and aims to estimate the market size and future growth potential of various market segments, based on type, application, disease, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
“The Instruments segment accounted for a substantial share of the clinical microbiology market, by type in 2023.”
The instruments segment is projected to dominate the clinical microbiology industry throughout the forecast period. This segment's substantial market share can be attributed to several factors. Firstly, there is significant adoption of conventional laboratory instruments by researchers and academia, with a notable increase in industry-academia collaborations focused on genomic research. Secondly, advancements in molecular techniques and proteomics, including innovations such as integrating microfluidics with PCR and applying nanotechnology to qPCR techniques, are driving the segment's growth. Lastly, the ongoing trend of laboratory automation among clinical laboratories is contributing to the expansion and prominence of the instruments segment within the clinical microbiology industry.
“ By Application Pharmaceutical Application segment accounted for the largest share in the healthcare clinical microbiology market.”
The pharmaceuticals segment represents the largest application area within the clinical microbiology industry and is expected to maintain its dominance throughout the forecast period. This significant share can be primarily attributed to the presence of well-established and widely accepted regulations governing microbial contamination evaluation during pharmaceutical manufacturing and raw material procurement. Regulatory bodies such as the WHO, FDA, MHRA (UK), European Medicines Agency (EU), TGA (Australia), and ANVISA (Brazil) have defined stringent guidelines for assessing microbial contamination in excipients and active pharmaceutical ingredients (APIs) to ensure sterile drug manufacturing and microbial load testing of finished pharmaceutical products. Moreover, pharmaceutical manufacturing processes are rigorously monitored and controlled according to various pharmacopeias on a global scale. The increasing production volume of pharmaceutical drugs worldwide also contributes significantly to the growth of this application segment.
“North America to witness the substantial growth rate during the forecast period.”
North America, which includes the United States and Canada, holds a leading position in the clinical microbiology market. This region is characterized by its maturity, marked by widespread use of clinical microbiology technologies among key end-users such as hospitals, research laboratories, diagnostic centers, and commercial service providers. Additionally, North America benefits from well-established distribution channels for manufacturers and suppliers of clinical microbiology products. The region's growth is propelled by factors including easy accessibility to and high adoption of advanced diagnostic technologies, supported by substantial per capita healthcare expenditure by the US and Canadian governments annually, along with favorable government regulations that foster industry development.
The break-down of primary participants is as mentioned below:
- By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
- By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
- By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, ROW-10%
The prominent players in the global healthcare clinical microbiology market include BioMйrieux (France), Danaher Corporation (US), Becton, Dickinson, and Company (BD) (US), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Bruker (US), Hologic, Inc. (US), Merck KGaA(Germany), Bio-Rad Laboratories, Inc.(US), QIAGEN(Netherlands), Shimadzu Corporation(Japan), Neogen Corporation (US), Siemens Healthineers AG (Germany). With Emerging players including, Hardy Diagnostics (US), EMSL Analytical, Inc. (US), Lofilchem S.R.L (Italy), TCS Biosciences (UK), Cole-Parmer Instrument Company, LLC (US), Memmert GmbH + Co.KG (Germany), Vacutest Kima S.r.l (Germany), Rapid Micro Biosystems, Inc. (US), Biotechnology Solutions TX, LLC (US), and Arrow Diagnostics Srl (Italy).
Research Coverage:
The report analyzes the Clinical microbiology market and aims to estimate the market size and future growth potential of various market segments, based on type, application, disease, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
- Analysis of Market Dynamics (Rising incidence of infectious diseases, technological advancements in disease diagnostics,), restraints (limited reimbursement policies for clinical microbiology testing products), opportunities (Improving healthcare infrastructure among emerging economies), and challenges (operational barriers related to use of diagnostics tests)
- Products/Innovations: Detailed insights on upcoming technologies, research & development activities, and new service launches in the Clinical microbiology market.
- Market Development: Comprehensive information on the lucrative emerging markets, component, demographics , end-user, and region.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the clinical microbiology market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the clinical microbiology market like BioMйrieux (France), Danaher Corporation (US), Becton, Dickinson, and Company (BD) (US), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Bruker (US), Hologic, Inc. (US) among others.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
TABLE 1 CLINICAL MICROBIOLOGY MARKET: INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 SEGMENTS COVERED
FIGURE 1 CLINICAL MICROBIOLOGY MARKET: SEGMENTS COVERED
1.3.2 REGIONS COVERED
FIGURE 2 CLINICAL MICROBIOLOGY MARKET: REGIONS COVERED
1.3.3 YEARS CONSIDERED
FIGURE 3 CLINICAL MICROBIOLOGY MARKET: YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.3.5 UNITS CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.5.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 4 CLINICAL MICROBIOLOGY MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 List of key secondary sources
2.1.1.2 Key data from secondary sources
2.1.1.3 Objectives of secondary research
2.1.2 PRIMARY DATA
FIGURE 5 KEY PRIMARY SOURCES FROM DEMAND AND SUPPLY SIDES
2.1.2.1 Objectives of primary research
2.1.2.2 Key data from primary sources
TABLE 2 KEY DATA OBTAINED FROM PRIMARY SOURCES
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primaries
FIGURE 6 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Company revenue estimation approach
FIGURE 8 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.2.1.2 Company presentations and primary interviews
2.2.1.3 Growth forecast
2.2.1.4 CAGR projections
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.2 TOP-DOWN APPROACH
FIGURE 10 CLINICAL MICROBIOLOGY MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 RISK ASSESSMENT
TABLE 3 CLINICAL MICROBIOLOGY MARKET: RISK ASSESSMENT
2.9 IMPACT OF ECONOMIC RECESSION ON CLINICAL MICROBIOLOGY MARKET
3 EXECUTIVE SUMMARY
FIGURE 12 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 13 LABORATORY INSTRUMENTS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 14 MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 CLINICAL MICROBIOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 16 REGIONAL SNAPSHOT OF CLINICAL MICROBIOLOGY MARKET
4 PREMIUM INSIGHTS
4.1 CLINICAL MICROBIOLOGY MARKET OVERVIEW
FIGURE 17 HIGH PREVALENCE OF INFECTIOUS DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
4.2 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT AND COUNTRY (2023)
FIGURE 18 GERMANY AND INSTRUMENTS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
4.3 CLINICAL MICROBIOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 CHINA TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD
4.4 CLINICAL MICROBIOLOGY MARKET: REGIONAL MIX (2022–2029)
FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.5 CLINICAL MICROBIOLOGY MARKET: DEVELOPED VS. EMERGING MARKETS (2024 VS. 2029)
FIGURE 21 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 CLINICAL MICROBIOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Technological advancements in clinical diagnosis and novel molecular diagnostic-based instruments
5.2.1.2 Rising incidence of infectious diseases and epidemics
5.2.1.3 Increasing R&D programs and public-private investments
5.2.2 RESTRAINTS
5.2.2.1 Limited reimbursement policies for clinical microbiology testing procedures
5.2.3 OPPORTUNITIES
5.2.3.1 Improved healthcare infrastructure in emerging countries
5.2.4 CHALLENGES
5.2.4.1 Operational barriers to diagnostic microbiology tests in emerging countries
5.3 PRICING ANALYSIS
TABLE 4 AVERAGE SELLING PRICE FOR CLINICAL MICROBIOLOGY TESTING PRODUCTS, 2021–2023
FIGURE 23 AVERAGE SELLING PRICE OF CLINICAL MICROBIOLOGY INSTRUMENTS, BY REGION (USD THOUSAND)
TABLE 5 AVERAGE SELLING PRICE OF CLINICAL MICROBIOLOGY INSTRUMENTS, BY REGION, 2021–2023
5.4 PATENT ANALYSIS
FIGURE 24 PATENT ANALYSIS FOR PCR SYSTEMS (JANUARY 2014–APRIL 2024)
5.4.1 LIST OF MAJOR PATENTS, 2022–2023
TABLE 6 LIST OF MAJOR PATENTS IN CLINICAL MICROBIOLOGY MARKET, JANUARY 2022–DECEMBER 2023
5.5 VALUE CHAIN ANALYSIS
FIGURE 25 CLINICAL MICROBIOLOGY MARKET: VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 26 CLINICAL MICROBIOLOGY MARKET: SUPPLY CHAIN ANALYSIS
5.7 TRADE ANALYSIS
5.7.1 TRADE ANALYSIS FOR MICROSCOPES
FIGURE 27 IMPORT DATA FOR MICROSCOPES, BY COUNTRY, 2019–2023 (USD THOUSAND)
FIGURE 28 EXPORT DATA FOR MICROSCOPES, BY COUNTRY, 2019–2023 (USD THOUSAND)
5.7.2 TRADE ANALYSIS FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS
FIGURE 29 IMPORT DATA FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2019–2023 (USD THOUSAND)
FIGURE 30 EXPORT DATA FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2019–2023 (USD THOUSAND)
5.7.3 TRADE ANALYSIS FOR MEDICAL, SURGICAL, OR LABORATORY STERILIZERS
FIGURE 31 IMPORT DATA FOR MEDICAL, SURGICAL, OR LABORATORY STERILIZERS, BY COUNTRY, 2019–2023 (USD THOUSAND)
FIGURE 32 EXPORT DATA FOR MEDICAL, SURGICAL, OR LABORATORY STERILIZERS, BY COUNTRY, 2019–2023 (USD THOUSAND)
5.8 ECOSYSTEM ANALYSIS
FIGURE 33 CLINICAL MICROBIOLOGY MARKET: ECOSYSTEM MAP
5.8.1 ROLE IN ECOSYSTEM
TABLE 7 CLINICAL MICROBIOLOGY MARKET: ROLE IN ECOSYSTEM
5.9 PORTER’S FIVE FORCES ANALYSIS
FIGURE 34 CLINICAL MICROBIOLOGY MARKET: PORTER’S FIVE FORCES
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 35 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
5.10.2 KEY BUYING CRITERIA
FIGURE 36 KEY BUYING CRITERIA FOR CLINICAL MICROBIOLOGY PRODUCTS
TABLE 10 KEY BUYING CRITERIA FOR CLINICAL MICROBIOLOGY PRODUCTS
5.11 REGULATORY LANDSCAPE
5.11.1 REGULATORY ANALYSIS
5.11.1.1 North America
5.11.1.1.1 US
5.11.1.2 Europe
5.11.1.3 Asia Pacific
5.11.1.4 Rest of the World
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.2.1 North America: Regulatory bodies, government agencies, and other organizations
5.11.2.2 Europe: Regulatory bodies, government agencies, and other organizations
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.2.3 Asia Pacific: Regulatory bodies, government agencies, and other organizations
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.2.4 Latin America: Regulatory bodies, government agencies, and other organizations
5.11.2.5 Rest of the World: Regulatory bodies, government agencies, and other organizations
5.12 TECHNOLOGY ANALYSIS
5.12.1 KEY TECHNOLOGIES
5.12.1.1 MALDI-TOF mass spectrometry
5.12.2 COMPLEMENTARY TECHNOLOGIES
5.12.2.1 Optical immunosensors
5.12.2.2 Electrochemical immunosensors
5.12.3 ADJACENT TECHNOLOGIES
5.12.3.1 Automated multiplex PCR systems
5.13 KEY CONFERENCES & EVENTS, 2024–2025
TABLE 16 CLINICAL MICROBIOLOGY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2025
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 37 REVENUE SHIFT IN CLINICAL MICROBIOLOGY MARKET
5.15 INVESTMENT AND FUNDING SCENARIO
5.15.1 NUMBER OF DEALS
FIGURE 38 CLINICAL MICROBIOLOGY MARKET: NUMBER OF DEALS BY KEY PLAYERS, 2018–2022
5.15.2 VALUE OF INVESTOR DEALS
FIGURE 39 CLINICAL MICROBIOLOGY MARKET: VALUE OF INVESTOR DEALS, 2018–2022 (USD MILLION)
5.16 UNMET NEEDS
6 CLINICAL MICROBIOLOGY MARKET, BY APPLICATION
6.1 INTRODUCTION
TABLE 17 CLINICAL MICROBIOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
6.2 PHARMACEUTICAL APPLICATIONS
6.2.1 PRESENCE OF WELL-ESTABLISHED PLAYERS AND INCREASED DRUG DEVELOPMENT PIPELINE TO AID MARKET GROWTH
TABLE 18 CLINICAL MICROBIOLOGY MARKET FOR PHARMACEUTICAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
6.3 CLINICAL APPLICATIONS
6.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND INCREASING FOCUS ON EARLY DIAGNOSIS TO DRIVE MARKET
TABLE 19 CLINICAL MICROBIOLOGY MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
6.4 FOOD TESTING APPLICATIONS
6.4.1 HIGH DEMAND FOR PACKAGED FOOD AND EXPANSION OF DAIRY INDUSTRY TO SUPPORT MARKET GROWTH
TABLE 20 CLINICAL MICROBIOLOGY MARKET FOR FOOD TESTING APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
6.5 ENERGY APPLICATIONS
6.5.1 INCREASING FOCUS ON ENERGY-EFFICIENT BIOFUEL DEVELOPMENT TO BOOST MARKET GROWTH
TABLE 21 CLINICAL MICROBIOLOGY MARKET FOR ENERGY APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
6.6 CHEMICAL & MATERIAL MANUFACTURING APPLICATIONS
6.6.1 INCREASED USE OF MICROBE-DERIVED DYES TO FUEL MARKET GROWTH
TABLE 22 CLINICAL MICROBIOLOGY MARKET FOR CHEMICAL & MATERIAL MANUFACTURING APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
6.7 ENVIRONMENTAL APPLICATIONS
6.7.1 RISING PREVALENCE OF AIR- AND WATER-BORNE DISEASES TO PROPEL MARKET GROWTH
TABLE 23 CLINICAL MICROBIOLOGY MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
7 CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA
7.1 INTRODUCTION
TABLE 24 CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
7.2 RESPIRATORY DISEASES
7.2.1 INCREASING CLINICAL RESEARCH ACTIVITIES FOR ADVANCED DRUG DEVELOPMENT TO DRIVE MARKET
TABLE 25 CLINICAL MICROBIOLOGY MARKET FOR RESPIRATORY DISEASES, BY REGION, 2022–2029 (USD MILLION)
7.3 BLOODSTREAM INFECTIONS
7.3.1 GROWING INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS TO PROPEL MARKET GROWTH
TABLE 26 CLINICAL MICROBIOLOGY MARKET FOR BLOODSTREAM INFECTIONS, BY REGION, 2022–2029 (USD MILLION)
7.4 GASTROINTESTINAL DISEASES
7.4.1 HIGH RISK OF FOOD- AND WATER-BORNE INFECTIONS TO AID MARKET GROWTH
TABLE 27 CLINICAL MICROBIOLOGY MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
7.5 SEXUALLY TRANSMITTED DISEASES
7.5.1 INCREASING EMPHASIS ON EARLY AND EFFECTIVE DISEASE DIAGNOSIS TO BOOST MARKET GROWTH
TABLE 28 CLINICAL MICROBIOLOGY MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2022–2029 (USD MILLION)
7.6 URINARY TRACT INFECTIONS
7.6.1 RISING NUMBER OF CLINICAL TRIALS FOR DEVELOPMENT OF NEW ANTIBIOTICS TO SUPPORT MARKET GROWTH
TABLE 29 CLINICAL MICROBIOLOGY MARKET FOR URINARY TRACT INFECTIONS, BY REGION, 2022–2029 (USD MILLION)
7.7 PERIODONTAL DISEASES
7.7.1 INCREASING R&D INITIATIVES TO STUDY MICROBE-INDUCED DISEASES TO FUEL MARKET GROWTH
TABLE 30 CLINICAL MICROBIOLOGY MARKET FOR PERIODONTAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
7.8 OTHER DISEASES
TABLE 31 CLINICAL MICROBIOLOGY MARKET FOR OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION)
8 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT
8.1 INTRODUCTION
TABLE 32 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
8.2 INSTRUMENTS
TABLE 33 CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 34 CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 35 CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY END USER, 2022–2029 (USD MILLION)
TABLE 36 CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY REGION, 2022–2029 (USD MILLION)
8.2.1 LABORATORY INSTRUMENTS
TABLE 37 LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 38 LABORATORY INSTRUMENTS MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 39 LABORATORY INSTRUMENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 40 LABORATORY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.1 Incubators
8.2.1.1.1 Rising demand for cell culture applications to drive segment
TABLE 41 INCUBATORS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.2 Gram stainers
8.2.1.2.1 Faster and more accurate screening of bacterial pathogens to propel segment growth
TABLE 42 GRAM STAINERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.3 Bacterial colony counters
8.2.1.3.1 Increased focus on accurate bacterial quantification to fuel segment growth
TABLE 43 BACTERIAL COLONY COUNTERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.4 Autoclave sterilizers
8.2.1.4.1 Growing need for infection control in healthcare facilities to support market growth
TABLE 44 AUTOCLAVE STERILIZERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.5 Microbial air samplers
8.2.1.5.1 Need for enhanced air quality monitoring in cleanrooms to accelerate segment growth
TABLE 45 MICROBIAL AIR SAMPLERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.6 Anaerobic culture systems
8.2.1.6.1 Increased research on anaerobic microorganisms to boost segment growth
TABLE 46 ANAEROBIC CULTURE SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.7 Petri dish fillers
8.2.1.7.1 Need for minimal bench space and effective control with graphical user interfaces to aid segment growth
TABLE 47 PETRI DISH FILLERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.8 Blood culture systems
8.2.1.8.1 Technological advancements in diagnostic testing to drive segment
TABLE 48 BLOOD CULTURE SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.9 Microbial culture systems
8.2.1.9.1 Increase in biopharmaceutical research to augment segment growth
TABLE 49 MICROBIAL CULTURE SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.10 Other laboratory instruments
TABLE 50 OTHER LABORATORY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.2 MICROBIOLOGY ANALYZERS
TABLE 51 LIST OF COMMERCIALLY AVAILABLE MICROBIOLOGY ANALYZERS, 2023–2024
TABLE 52 MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 53 MICROBIOLOGY ANALYZERS MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 54 MICROBIOLOGY ANALYZERS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 55 MICROBIOLOGY ANALYZERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.2.1 Molecular diagnostic instruments
8.2.2.1.1 Advancements in multiplexing techniques and high adoption of genomics-based analysis to aid market growth
TABLE 56 MOLECULAR DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.2.2 Microscopes
8.2.2.2.1 Rising demand for high-resolution imaging to propel market growth
TABLE 57 MICROSCOPES MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.2.3 Mass spectrometers
8.2.2.3.1 Increased applications in proteomics and metabolomics to boost market growth
TABLE 58 MASS SPECTROMETERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3 REAGENTS
TABLE 59 CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 60 CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 61 CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY END USER, 2022–2029 (USD MILLION)
TABLE 62 CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY REGION, 2022–2029 (USD MILLION)
8.3.1 PATHOGEN-SPECIFIC KITS
8.3.1.1 Growing private-public initiatives for research to support market growth
TABLE 63 PATHOGEN-SPECIFIC KITS MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 64 PATHOGEN-SPECIFIC KITS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 65 PATHOGEN-SPECIFIC KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3.2 GENERAL REAGENTS
8.3.2.1 Rising demand for diagnostic tests for pathogen detection to propel segment growth
TABLE 66 GENERAL REAGENTS MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 67 GENERAL REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 68 GENERAL REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.4 MEDIA & SERA
8.4.1 RISING DEMAND FOR STANDARDIZED CULTURE MEDIA FOR MICROBIOLOGICAL TESTING TO DRIVE MARKET
TABLE 69 CLINICAL MICROBIOLOGY MARKET FOR MEDIA & SERA, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 70 CLINICAL MICROBIOLOGY MARKET FOR MEDIA & SERA, BY END USER, 2022–2029 (USD MILLION)
TABLE 71 CLINICAL MICROBIOLOGY MARKET FOR MEDIA & SERA, BY REGION, 2022–2029 (USD MILLION)
9 CLINICAL MICROBIOLOGY MARKET, BY END USER
9.1 INTRODUCTION
TABLE 72 NUMBER OF CLINICAL LABORATORIES, BY TIER, 2023
TABLE 73 CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
9.2 HOSPITALS & DIAGNOSTIC CENTERS
9.2.1 GROWING INCIDENCE OF TARGET DISEASES TO DRIVE MARKET
TABLE 74 CLINICAL MICROBIOLOGY MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2022–2029 (USD MILLION)
9.3 CONTRACT TESTING LABORATORIES
9.3.1 CONTINUOUS OUTSOURCING OF DRUG TESTING PROCEDURES TO LABORATORY SERVICE PROVIDERS TO AID MARKET GROWTH
TABLE 75 CLINICAL MICROBIOLOGY MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 INCREASED USE OF ADVANCED MOLECULAR DIAGNOSTIC PRODUCTS FOR DISEASE DIAGNOSIS TO AUGMENT MARKET GROWTH
TABLE 76 CLINICAL MICROBIOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
10 CLINICAL MICROBIOLOGY MARKET, BY REGION
10.1 INTRODUCTION
TABLE 77 SALES VOLUME IN US, UK, AND CHINA, BY PRODUCT TYPE (2023)
TABLE 78 CLINICAL MICROBIOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 40 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET SNAPSHOT
TABLE 79 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 80 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 81 NORTH AMERICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 82 NORTH AMERICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 83 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 84 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 85 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022–2029(USD MILLION)
TABLE 86 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 US to dominate clinical microbiology market during study period
TABLE 87 US: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 88 US: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 89 US: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 90 US: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 91 US: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Supportive government initiatives and increased research funding to boost market growth
TABLE 92 CANADA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 93 CANADA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 94 CANADA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 95 CANADA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 96 CANADA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.3 EUROPE
TABLE 97 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 98 EUROPE: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 99 EUROPE: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 100 EUROPE: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 101 EUROPE: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 102 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 103 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 104 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Growing outsourcing of diagnostic testing by hospitals to fuel market growth
TABLE 105 GERMANY: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 106 GERMANY: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 107 GERMANY: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 108 GERMANY: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 109 GERMANY: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.3.3 UK
10.3.3.1 Rising acceptance of genome-based diagnostic techniques to fuel market growth
TABLE 110 UK: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 111 UK: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 112 UK: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 113 UK: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 114 UK: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Favorable healthcare reforms and investments in diagnostic infrastructure to propel market growth
TABLE 115 FRANCE: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 116 FRANCE: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 117 FRANCE: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 118 FRANCE: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 119 FRANCE: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Improved healthcare services and better disease surveillance to fuel market growth
TABLE 120 ITALY: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 121 ITALY: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 122 ITALY: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 123 ITALY: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 124 ITALY: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Well-established research centers and stringent food regulations to augment market growth
TABLE 125 SPAIN: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 126 SPAIN: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 127 SPAIN: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 128 SPAIN: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 129 SPAIN: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 130 REST OF EUROPE: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029(USD MILLION)
TABLE 131 REST OF EUROPE: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 132 REST OF EUROPE: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 133 REST OF EUROPE: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 134 REST OF EUROPE: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 41 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET SNAPSHOT
TABLE 135 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029(USD MILLION)
TABLE 136 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 137 ASIA PACIFIC: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 139 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 140 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 141 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 142 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 JAPAN
10.4.2.1 Technological advancements in healthcare and high geriatric population to aid market growth
TABLE 143 JAPAN: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 144 JAPAN: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 145 JAPAN: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 146 JAPAN: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 147 JAPAN: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Increasing government focus on disease prevention to drive market
TABLE 148 CHINA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 149 CHINA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 150 CHINA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 151 CHINA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 152 CHINA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Rapidly increasing population and high incidence of infectious diseases to propel market growth
TABLE 153 INDIA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 154 INDIA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 155 INDIA LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 156 INDIA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 157 INDIA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.4.5 AUSTRALIA
10.4.5.1 Rising public-private investments and growing research on diagnostic applications to drive market
TABLE 158 AUSTRALIA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 159 AUSTRALIA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 160 AUSTRALIA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 161 AUSTRALIA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 162 AUSTRALIA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.4.6 SOUTH KOREA
10.4.6.1 Strong government support and increased adoption of advanced diagnostic technologies to aid market growth
TABLE 163 SOUTH KOREA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 164 SOUTH KOREA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 165 SOUTH KOREA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 166 SOUTH KOREA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 167 SOUTH KOREA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.4.7 REST OF ASIA PACIFIC
TABLE 168 REST OF ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 169 REST OF ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 REST OF ASIA PACIFIC: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 171 REST OF ASIA PACIFIC: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 172 REST OF ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.5 LATIN AMERICA
TABLE 173 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 174 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 175 LATIN AMERICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 176 LATIN AMERICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 177 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 178 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 179 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 180 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
10.5.1 LATIN AMERICA: RECESSION IMPACT
10.5.2 BRAZIL
10.5.2.1 High healthcare expenditure and presence of key manufacturers to support market growth
TABLE 181 BRAZIL: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 182 BRAZIL: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 183 BRAZIL: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 184 BRAZIL: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 185 BRAZIL: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.5.3 MEXICO
10.5.3.1 Supportive government initiatives and increased healthcare investments to augment market growth
TABLE 186 MEXICO: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 187 MEXICO: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 188 MEXICO: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 189 MEXICO: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 190 MEXICO: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.5.4 REST OF LATIN AMERICA
TABLE 191 REST OF LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 192 REST OF LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 193 REST OF LATIN AMERICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 194 REST OF LATIN AMERICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 195 REST OF LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
TABLE 196 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 197 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 198 MIDDLE EAST & AFRICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 199 MIDDLE EAST & AFRICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 200 MIDDLE EAST AND AFRICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 201 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 202 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 203 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022–2029(USD MILLION)
10.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
10.6.2 GCC COUNTRIES
10.6.2.1 High incidence of infectious diseases and technological advancements to fuel market growth
TABLE 204 GCC COUNTRIES: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 205 GCC COUNTRIES: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 206 GCC COUNTRIES: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 207 GCC COUNTRIES: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 208 GCC COUNTRIES: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.6.3 REST OF MIDDLE EAST & AFRICA
TABLE 209 REST OF MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029(USD MILLION)
TABLE 210 REST OF MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 211 REST OF MIDDLE EAST & AFRICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 212 REST OF MIDDLE EAST & AFRICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 213 REST OF MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL MICROBIOLOGY MARKET
FIGURE 42 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
11.3 REVENUE ANALYSIS
FIGURE 43 REVENUE ANALYSIS FOR KEY PLAYERS IN CLINICAL MICROBIOLOGY MARKET (2021–2023)
11.4 MARKET SHARE ANALYSIS
FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CLINICAL MICROBIOLOGY MARKET (2023)
TABLE 214 CLINICAL MICROBIOLOGY MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 PERVASIVE PLAYERS
11.5.3 EMERGING LEADERS
11.5.4 PARTICIPANTS
FIGURE 45 CLINICAL MICROBIOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
FIGURE 46 CLINICAL MICROBIOLOGY MARKET: COMPANY FOOTPRINT
11.5.5.2 Product footprint
TABLE 215 CLINICAL MICROBIOLOGY MARKET: PRODUCT FOOTPRINT
11.5.5.3 Application footprint
TABLE 216 CLINICAL MICROBIOLOGY MARKET: APPLICATION FOOTPRINT
11.5.5.4 End user footprint
TABLE 217 CLINICAL MICROBIOLOGY MARKET: END USER FOOTPRINT
11.5.5.5 Region footprint
TABLE 218 CLINICAL MICROBIOLOGY MARKET: REGION FOOTPRINT
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 DYNAMIC COMPANIES
11.6.3 RESPONSIVE COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 47 CLINICAL MICROBIOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
TABLE 219 CLINICAL MICROBIOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 220 CLINICAL MICROBIOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
11.7 VALUATION & FINANCIAL METRICS
FIGURE 48 EV/EBITDA OF KEY VENDORS
FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
11.8 BRAND/PRODUCT COMPARISON
FIGURE 50 CLINICAL MICROBIOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES
TABLE 221 CLINICAL MICROBIOLOGY MARKET: PRODUCTS LAUNCHES,
JANUARY 2021–MAY 2024
11.9.2 DEALS
TABLE 222 CLINICAL MICROBIOLOGY MARKET: DEALS, JANUARY 2021–MAY 2024
11.9.3 OTHER DEVELOPMENTS
TABLE 223 CLINICAL MICROBIOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 BIOMЙRIEUX
TABLE 224 BIOMЙRIEUX: COMPANY OVERVIEW
FIGURE 51 BIOMЙRIEUX: COMPANY SNAPSHOT (2023)
TABLE 225 BIOMЙRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 226 BIOMЙRIEUX: DEALS, JANUARY 2021–MAY 2024
12.1.2 DANAHER CORPORATION
TABLE 227 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 52 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 228 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 229 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.3 BECTON, DICKINSON AND COMPANY
FIGURE 53 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
TABLE 231 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 232 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024
TABLE 233 BECKTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021–MAY 2024
TABLE 234 BECKTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.4 ABBOTT
FIGURE 54 ABBOTT: COMPANY SNAPSHOT (2023)
TABLE 236 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 237 ABBOTT: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.5 F. HOFFMANN-LA ROCHE LTD.
FIGURE 55 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
TABLE 239 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 240 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES,
JANUARY 2021–MAY 2024
TABLE 241 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–MAY 2024
TABLE 242 F. HOFFMAN-LA ROCHE LTD.: OTHER DEVELOPMENTS,
JANUARY 2021–MAY 2024
12.1.6 THERMO FISHER SCIENTIFIC INC.
TABLE 243 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 56 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 244 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 245 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024
TABLE 246 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–MAY 2024
12.1.7 AGILENT TECHNOLOGIES, INC.
FIGURE 57 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 248 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 249 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021–MAY 2024
12.1.8 BRUKER
TABLE 250 BRUKER: COMPANY OVERVIEW
FIGURE 58 BRUKER: COMPANY SNAPSHOT (2022)
TABLE 251 BRUKER: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 252 BRUKER: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024
TABLE 253 BRUKER: DEALS, JANUARY 2021–MAY 2024
12.1.9 HOLOGIC, INC.
TABLE 254 HOLOGIC, INC.: COMPANY OVERVIEW
FIGURE 59 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
TABLE 255 HOLOGIC, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 256 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024
TABLE 257 HOLOGIC, INC.: DEALS, JANUARY 2021–MAY 2024
12.1.10 MERCK KGAA
TABLE 258 MERCK KGAA: COMPANY OVERVIEW
FIGURE 60 MERCK KGAA: COMPANY SNAPSHOT (2022)
TABLE 259 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 260 MERCK KGAA: DEALS, JANUARY 2021–MAY 2024
TABLE 261 MERCK KGAA: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.11 BIO-RAD LABORATORIES, INC.
TABLE 262 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 61 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 263 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 264 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021–MAY 2024
TABLE 265 BIO-RAD LABORATORIES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.12 QIAGEN
TABLE 266 QIAGEN: COMPANY OVERVIEW
FIGURE 62 QIAGEN: COMPANY SNAPSHOT (2023)
TABLE 267 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 268 QIAGEN: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024
TABLE 269 QIAGEN: DEALS, JANUARY 2021–MAY 2024
12.1.13 SHIMADZU CORPORATION
TABLE 270 SHIMADZU CORPORATION: COMPANY OVERVIEW
FIGURE 63 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 271 SHIMADZU CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.14 NEOGEN CORPORATION
TABLE 272 NEOGEN CORPORATION: COMPANY OVERVIEW
FIGURE 64 NEOGEN CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 273 NEOGEN CORPORATION: PRODUCTS/ SERVICES/SOLUTIONS OFFERED
TABLE 274 NEOGEN CORPORATION: DEALS, JANUARY 2021–MAY 2024
12.1.15 SIEMENS HEALTHINEERS AG
TABLE 275 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
FIGURE 65 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
TABLE 276 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.16 HARDY DIAGNOSTICS
TABLE 277 HARDY DIAGNOSTICS: COMPANY OVERVIEW
TABLE 278 HARDY DIAGNOSTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.17 EMSL ANALYTICAL, INC.
TABLE 279 EMSL ANALYTICAL, INC.: COMPANY OVERVIEW
TABLE 280 EMSL ANALYTICAL, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.18 LIOFILCHEM SRL
TABLE 281 LIOFILCHEM SRL: COMPANY OVERVIEW
TABLE 282 LIOFILCHEM SRL: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.19 TCS BIOSCIENCES
TABLE 283 TCS BIOSCIENCES: COMPANY OVERVIEW
TABLE 284 TCS BIOSCIENCES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.20 COLE-PARMER INSTRUMENT COMPANY, LLC
TABLE 285 COLE-PARMER INSTRUMENT COMPANY, LLC: COMPANY OVERVIEW
TABLE 286 COLE-PARMER INSTRUMENT COMPANY, LLC: PRODUCTS/SERVICES/ SOLUTIONS OFFERED
12.2 OTHER PLAYERS
12.2.1 MEMMERT GMBH + CO.KG
TABLE 287 MEMMERT GMBH + CO.KG COMPANY OVERVIEW
12.2.2 VACUTEST KIMA S.R.L
TABLE 288 VACUTEST KIMA S.R.L.: COMPANY OVERVIEW
12.2.3 RAPID MICRO BIOSYSTEMS, INC.
TABLE 289 RAPID MICRO BIOSYSTEMS, INC..: COMPANY OVERVIEW
12.2.4 BIOTECHNOLOGY SOLUTIONS TX, LLC
TABLE 290 RAPID MICRO BIOSYSTEMS, INC.: COMPANY OVERVIEW
12.2.5 ARROW DIAGNOSTICS
TABLE 291 ARROW DIAGNOSTICS: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
TABLE 1 CLINICAL MICROBIOLOGY MARKET: INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 SEGMENTS COVERED
FIGURE 1 CLINICAL MICROBIOLOGY MARKET: SEGMENTS COVERED
1.3.2 REGIONS COVERED
FIGURE 2 CLINICAL MICROBIOLOGY MARKET: REGIONS COVERED
1.3.3 YEARS CONSIDERED
FIGURE 3 CLINICAL MICROBIOLOGY MARKET: YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.3.5 UNITS CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
1.5.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 4 CLINICAL MICROBIOLOGY MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 List of key secondary sources
2.1.1.2 Key data from secondary sources
2.1.1.3 Objectives of secondary research
2.1.2 PRIMARY DATA
FIGURE 5 KEY PRIMARY SOURCES FROM DEMAND AND SUPPLY SIDES
2.1.2.1 Objectives of primary research
2.1.2.2 Key data from primary sources
TABLE 2 KEY DATA OBTAINED FROM PRIMARY SOURCES
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primaries
FIGURE 6 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Company revenue estimation approach
FIGURE 8 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.2.1.2 Company presentations and primary interviews
2.2.1.3 Growth forecast
2.2.1.4 CAGR projections
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.2 TOP-DOWN APPROACH
FIGURE 10 CLINICAL MICROBIOLOGY MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 RISK ASSESSMENT
TABLE 3 CLINICAL MICROBIOLOGY MARKET: RISK ASSESSMENT
2.9 IMPACT OF ECONOMIC RECESSION ON CLINICAL MICROBIOLOGY MARKET
3 EXECUTIVE SUMMARY
FIGURE 12 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 13 LABORATORY INSTRUMENTS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 14 MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 CLINICAL MICROBIOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 16 REGIONAL SNAPSHOT OF CLINICAL MICROBIOLOGY MARKET
4 PREMIUM INSIGHTS
4.1 CLINICAL MICROBIOLOGY MARKET OVERVIEW
FIGURE 17 HIGH PREVALENCE OF INFECTIOUS DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
4.2 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT AND COUNTRY (2023)
FIGURE 18 GERMANY AND INSTRUMENTS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
4.3 CLINICAL MICROBIOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 CHINA TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD
4.4 CLINICAL MICROBIOLOGY MARKET: REGIONAL MIX (2022–2029)
FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.5 CLINICAL MICROBIOLOGY MARKET: DEVELOPED VS. EMERGING MARKETS (2024 VS. 2029)
FIGURE 21 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 CLINICAL MICROBIOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Technological advancements in clinical diagnosis and novel molecular diagnostic-based instruments
5.2.1.2 Rising incidence of infectious diseases and epidemics
5.2.1.3 Increasing R&D programs and public-private investments
5.2.2 RESTRAINTS
5.2.2.1 Limited reimbursement policies for clinical microbiology testing procedures
5.2.3 OPPORTUNITIES
5.2.3.1 Improved healthcare infrastructure in emerging countries
5.2.4 CHALLENGES
5.2.4.1 Operational barriers to diagnostic microbiology tests in emerging countries
5.3 PRICING ANALYSIS
TABLE 4 AVERAGE SELLING PRICE FOR CLINICAL MICROBIOLOGY TESTING PRODUCTS, 2021–2023
FIGURE 23 AVERAGE SELLING PRICE OF CLINICAL MICROBIOLOGY INSTRUMENTS, BY REGION (USD THOUSAND)
TABLE 5 AVERAGE SELLING PRICE OF CLINICAL MICROBIOLOGY INSTRUMENTS, BY REGION, 2021–2023
5.4 PATENT ANALYSIS
FIGURE 24 PATENT ANALYSIS FOR PCR SYSTEMS (JANUARY 2014–APRIL 2024)
5.4.1 LIST OF MAJOR PATENTS, 2022–2023
TABLE 6 LIST OF MAJOR PATENTS IN CLINICAL MICROBIOLOGY MARKET, JANUARY 2022–DECEMBER 2023
5.5 VALUE CHAIN ANALYSIS
FIGURE 25 CLINICAL MICROBIOLOGY MARKET: VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 26 CLINICAL MICROBIOLOGY MARKET: SUPPLY CHAIN ANALYSIS
5.7 TRADE ANALYSIS
5.7.1 TRADE ANALYSIS FOR MICROSCOPES
FIGURE 27 IMPORT DATA FOR MICROSCOPES, BY COUNTRY, 2019–2023 (USD THOUSAND)
FIGURE 28 EXPORT DATA FOR MICROSCOPES, BY COUNTRY, 2019–2023 (USD THOUSAND)
5.7.2 TRADE ANALYSIS FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS
FIGURE 29 IMPORT DATA FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2019–2023 (USD THOUSAND)
FIGURE 30 EXPORT DATA FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2019–2023 (USD THOUSAND)
5.7.3 TRADE ANALYSIS FOR MEDICAL, SURGICAL, OR LABORATORY STERILIZERS
FIGURE 31 IMPORT DATA FOR MEDICAL, SURGICAL, OR LABORATORY STERILIZERS, BY COUNTRY, 2019–2023 (USD THOUSAND)
FIGURE 32 EXPORT DATA FOR MEDICAL, SURGICAL, OR LABORATORY STERILIZERS, BY COUNTRY, 2019–2023 (USD THOUSAND)
5.8 ECOSYSTEM ANALYSIS
FIGURE 33 CLINICAL MICROBIOLOGY MARKET: ECOSYSTEM MAP
5.8.1 ROLE IN ECOSYSTEM
TABLE 7 CLINICAL MICROBIOLOGY MARKET: ROLE IN ECOSYSTEM
5.9 PORTER’S FIVE FORCES ANALYSIS
FIGURE 34 CLINICAL MICROBIOLOGY MARKET: PORTER’S FIVE FORCES
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF BUYERS
5.9.4 BARGAINING POWER OF SUPPLIERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 35 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
5.10.2 KEY BUYING CRITERIA
FIGURE 36 KEY BUYING CRITERIA FOR CLINICAL MICROBIOLOGY PRODUCTS
TABLE 10 KEY BUYING CRITERIA FOR CLINICAL MICROBIOLOGY PRODUCTS
5.11 REGULATORY LANDSCAPE
5.11.1 REGULATORY ANALYSIS
5.11.1.1 North America
5.11.1.1.1 US
5.11.1.2 Europe
5.11.1.3 Asia Pacific
5.11.1.4 Rest of the World
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.2.1 North America: Regulatory bodies, government agencies, and other organizations
5.11.2.2 Europe: Regulatory bodies, government agencies, and other organizations
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.2.3 Asia Pacific: Regulatory bodies, government agencies, and other organizations
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.2.4 Latin America: Regulatory bodies, government agencies, and other organizations
5.11.2.5 Rest of the World: Regulatory bodies, government agencies, and other organizations
5.12 TECHNOLOGY ANALYSIS
5.12.1 KEY TECHNOLOGIES
5.12.1.1 MALDI-TOF mass spectrometry
5.12.2 COMPLEMENTARY TECHNOLOGIES
5.12.2.1 Optical immunosensors
5.12.2.2 Electrochemical immunosensors
5.12.3 ADJACENT TECHNOLOGIES
5.12.3.1 Automated multiplex PCR systems
5.13 KEY CONFERENCES & EVENTS, 2024–2025
TABLE 16 CLINICAL MICROBIOLOGY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2025
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 37 REVENUE SHIFT IN CLINICAL MICROBIOLOGY MARKET
5.15 INVESTMENT AND FUNDING SCENARIO
5.15.1 NUMBER OF DEALS
FIGURE 38 CLINICAL MICROBIOLOGY MARKET: NUMBER OF DEALS BY KEY PLAYERS, 2018–2022
5.15.2 VALUE OF INVESTOR DEALS
FIGURE 39 CLINICAL MICROBIOLOGY MARKET: VALUE OF INVESTOR DEALS, 2018–2022 (USD MILLION)
5.16 UNMET NEEDS
6 CLINICAL MICROBIOLOGY MARKET, BY APPLICATION
6.1 INTRODUCTION
TABLE 17 CLINICAL MICROBIOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
6.2 PHARMACEUTICAL APPLICATIONS
6.2.1 PRESENCE OF WELL-ESTABLISHED PLAYERS AND INCREASED DRUG DEVELOPMENT PIPELINE TO AID MARKET GROWTH
TABLE 18 CLINICAL MICROBIOLOGY MARKET FOR PHARMACEUTICAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
6.3 CLINICAL APPLICATIONS
6.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND INCREASING FOCUS ON EARLY DIAGNOSIS TO DRIVE MARKET
TABLE 19 CLINICAL MICROBIOLOGY MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
6.4 FOOD TESTING APPLICATIONS
6.4.1 HIGH DEMAND FOR PACKAGED FOOD AND EXPANSION OF DAIRY INDUSTRY TO SUPPORT MARKET GROWTH
TABLE 20 CLINICAL MICROBIOLOGY MARKET FOR FOOD TESTING APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
6.5 ENERGY APPLICATIONS
6.5.1 INCREASING FOCUS ON ENERGY-EFFICIENT BIOFUEL DEVELOPMENT TO BOOST MARKET GROWTH
TABLE 21 CLINICAL MICROBIOLOGY MARKET FOR ENERGY APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
6.6 CHEMICAL & MATERIAL MANUFACTURING APPLICATIONS
6.6.1 INCREASED USE OF MICROBE-DERIVED DYES TO FUEL MARKET GROWTH
TABLE 22 CLINICAL MICROBIOLOGY MARKET FOR CHEMICAL & MATERIAL MANUFACTURING APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
6.7 ENVIRONMENTAL APPLICATIONS
6.7.1 RISING PREVALENCE OF AIR- AND WATER-BORNE DISEASES TO PROPEL MARKET GROWTH
TABLE 23 CLINICAL MICROBIOLOGY MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
7 CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA
7.1 INTRODUCTION
TABLE 24 CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
7.2 RESPIRATORY DISEASES
7.2.1 INCREASING CLINICAL RESEARCH ACTIVITIES FOR ADVANCED DRUG DEVELOPMENT TO DRIVE MARKET
TABLE 25 CLINICAL MICROBIOLOGY MARKET FOR RESPIRATORY DISEASES, BY REGION, 2022–2029 (USD MILLION)
7.3 BLOODSTREAM INFECTIONS
7.3.1 GROWING INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS TO PROPEL MARKET GROWTH
TABLE 26 CLINICAL MICROBIOLOGY MARKET FOR BLOODSTREAM INFECTIONS, BY REGION, 2022–2029 (USD MILLION)
7.4 GASTROINTESTINAL DISEASES
7.4.1 HIGH RISK OF FOOD- AND WATER-BORNE INFECTIONS TO AID MARKET GROWTH
TABLE 27 CLINICAL MICROBIOLOGY MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
7.5 SEXUALLY TRANSMITTED DISEASES
7.5.1 INCREASING EMPHASIS ON EARLY AND EFFECTIVE DISEASE DIAGNOSIS TO BOOST MARKET GROWTH
TABLE 28 CLINICAL MICROBIOLOGY MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2022–2029 (USD MILLION)
7.6 URINARY TRACT INFECTIONS
7.6.1 RISING NUMBER OF CLINICAL TRIALS FOR DEVELOPMENT OF NEW ANTIBIOTICS TO SUPPORT MARKET GROWTH
TABLE 29 CLINICAL MICROBIOLOGY MARKET FOR URINARY TRACT INFECTIONS, BY REGION, 2022–2029 (USD MILLION)
7.7 PERIODONTAL DISEASES
7.7.1 INCREASING R&D INITIATIVES TO STUDY MICROBE-INDUCED DISEASES TO FUEL MARKET GROWTH
TABLE 30 CLINICAL MICROBIOLOGY MARKET FOR PERIODONTAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
7.8 OTHER DISEASES
TABLE 31 CLINICAL MICROBIOLOGY MARKET FOR OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION)
8 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT
8.1 INTRODUCTION
TABLE 32 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
8.2 INSTRUMENTS
TABLE 33 CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 34 CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 35 CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY END USER, 2022–2029 (USD MILLION)
TABLE 36 CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY REGION, 2022–2029 (USD MILLION)
8.2.1 LABORATORY INSTRUMENTS
TABLE 37 LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 38 LABORATORY INSTRUMENTS MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 39 LABORATORY INSTRUMENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 40 LABORATORY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.1 Incubators
8.2.1.1.1 Rising demand for cell culture applications to drive segment
TABLE 41 INCUBATORS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.2 Gram stainers
8.2.1.2.1 Faster and more accurate screening of bacterial pathogens to propel segment growth
TABLE 42 GRAM STAINERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.3 Bacterial colony counters
8.2.1.3.1 Increased focus on accurate bacterial quantification to fuel segment growth
TABLE 43 BACTERIAL COLONY COUNTERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.4 Autoclave sterilizers
8.2.1.4.1 Growing need for infection control in healthcare facilities to support market growth
TABLE 44 AUTOCLAVE STERILIZERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.5 Microbial air samplers
8.2.1.5.1 Need for enhanced air quality monitoring in cleanrooms to accelerate segment growth
TABLE 45 MICROBIAL AIR SAMPLERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.6 Anaerobic culture systems
8.2.1.6.1 Increased research on anaerobic microorganisms to boost segment growth
TABLE 46 ANAEROBIC CULTURE SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.7 Petri dish fillers
8.2.1.7.1 Need for minimal bench space and effective control with graphical user interfaces to aid segment growth
TABLE 47 PETRI DISH FILLERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.8 Blood culture systems
8.2.1.8.1 Technological advancements in diagnostic testing to drive segment
TABLE 48 BLOOD CULTURE SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.9 Microbial culture systems
8.2.1.9.1 Increase in biopharmaceutical research to augment segment growth
TABLE 49 MICROBIAL CULTURE SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1.10 Other laboratory instruments
TABLE 50 OTHER LABORATORY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.2 MICROBIOLOGY ANALYZERS
TABLE 51 LIST OF COMMERCIALLY AVAILABLE MICROBIOLOGY ANALYZERS, 2023–2024
TABLE 52 MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 53 MICROBIOLOGY ANALYZERS MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 54 MICROBIOLOGY ANALYZERS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 55 MICROBIOLOGY ANALYZERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.2.1 Molecular diagnostic instruments
8.2.2.1.1 Advancements in multiplexing techniques and high adoption of genomics-based analysis to aid market growth
TABLE 56 MOLECULAR DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.2.2 Microscopes
8.2.2.2.1 Rising demand for high-resolution imaging to propel market growth
TABLE 57 MICROSCOPES MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.2.3 Mass spectrometers
8.2.2.3.1 Increased applications in proteomics and metabolomics to boost market growth
TABLE 58 MASS SPECTROMETERS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3 REAGENTS
TABLE 59 CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 60 CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 61 CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY END USER, 2022–2029 (USD MILLION)
TABLE 62 CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY REGION, 2022–2029 (USD MILLION)
8.3.1 PATHOGEN-SPECIFIC KITS
8.3.1.1 Growing private-public initiatives for research to support market growth
TABLE 63 PATHOGEN-SPECIFIC KITS MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 64 PATHOGEN-SPECIFIC KITS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 65 PATHOGEN-SPECIFIC KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3.2 GENERAL REAGENTS
8.3.2.1 Rising demand for diagnostic tests for pathogen detection to propel segment growth
TABLE 66 GENERAL REAGENTS MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 67 GENERAL REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 68 GENERAL REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.4 MEDIA & SERA
8.4.1 RISING DEMAND FOR STANDARDIZED CULTURE MEDIA FOR MICROBIOLOGICAL TESTING TO DRIVE MARKET
TABLE 69 CLINICAL MICROBIOLOGY MARKET FOR MEDIA & SERA, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 70 CLINICAL MICROBIOLOGY MARKET FOR MEDIA & SERA, BY END USER, 2022–2029 (USD MILLION)
TABLE 71 CLINICAL MICROBIOLOGY MARKET FOR MEDIA & SERA, BY REGION, 2022–2029 (USD MILLION)
9 CLINICAL MICROBIOLOGY MARKET, BY END USER
9.1 INTRODUCTION
TABLE 72 NUMBER OF CLINICAL LABORATORIES, BY TIER, 2023
TABLE 73 CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
9.2 HOSPITALS & DIAGNOSTIC CENTERS
9.2.1 GROWING INCIDENCE OF TARGET DISEASES TO DRIVE MARKET
TABLE 74 CLINICAL MICROBIOLOGY MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2022–2029 (USD MILLION)
9.3 CONTRACT TESTING LABORATORIES
9.3.1 CONTINUOUS OUTSOURCING OF DRUG TESTING PROCEDURES TO LABORATORY SERVICE PROVIDERS TO AID MARKET GROWTH
TABLE 75 CLINICAL MICROBIOLOGY MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 INCREASED USE OF ADVANCED MOLECULAR DIAGNOSTIC PRODUCTS FOR DISEASE DIAGNOSIS TO AUGMENT MARKET GROWTH
TABLE 76 CLINICAL MICROBIOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
10 CLINICAL MICROBIOLOGY MARKET, BY REGION
10.1 INTRODUCTION
TABLE 77 SALES VOLUME IN US, UK, AND CHINA, BY PRODUCT TYPE (2023)
TABLE 78 CLINICAL MICROBIOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 40 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET SNAPSHOT
TABLE 79 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 80 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 81 NORTH AMERICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 82 NORTH AMERICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 83 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 84 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 85 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022–2029(USD MILLION)
TABLE 86 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.2 US
10.2.2.1 US to dominate clinical microbiology market during study period
TABLE 87 US: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 88 US: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 89 US: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 90 US: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 91 US: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Supportive government initiatives and increased research funding to boost market growth
TABLE 92 CANADA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 93 CANADA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 94 CANADA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 95 CANADA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 96 CANADA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.3 EUROPE
TABLE 97 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 98 EUROPE: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 99 EUROPE: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 100 EUROPE: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 101 EUROPE: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 102 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 103 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 104 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
10.3.1 EUROPE: RECESSION IMPACT
10.3.2 GERMANY
10.3.2.1 Growing outsourcing of diagnostic testing by hospitals to fuel market growth
TABLE 105 GERMANY: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 106 GERMANY: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 107 GERMANY: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 108 GERMANY: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 109 GERMANY: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.3.3 UK
10.3.3.1 Rising acceptance of genome-based diagnostic techniques to fuel market growth
TABLE 110 UK: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 111 UK: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 112 UK: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 113 UK: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 114 UK: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.3.4 FRANCE
10.3.4.1 Favorable healthcare reforms and investments in diagnostic infrastructure to propel market growth
TABLE 115 FRANCE: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 116 FRANCE: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 117 FRANCE: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 118 FRANCE: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 119 FRANCE: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Improved healthcare services and better disease surveillance to fuel market growth
TABLE 120 ITALY: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 121 ITALY: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 122 ITALY: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 123 ITALY: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 124 ITALY: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Well-established research centers and stringent food regulations to augment market growth
TABLE 125 SPAIN: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 126 SPAIN: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 127 SPAIN: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 128 SPAIN: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 129 SPAIN: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 130 REST OF EUROPE: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029(USD MILLION)
TABLE 131 REST OF EUROPE: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 132 REST OF EUROPE: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 133 REST OF EUROPE: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 134 REST OF EUROPE: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 41 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET SNAPSHOT
TABLE 135 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029(USD MILLION)
TABLE 136 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 137 ASIA PACIFIC: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 139 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 140 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 141 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 142 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 JAPAN
10.4.2.1 Technological advancements in healthcare and high geriatric population to aid market growth
TABLE 143 JAPAN: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 144 JAPAN: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 145 JAPAN: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 146 JAPAN: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 147 JAPAN: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Increasing government focus on disease prevention to drive market
TABLE 148 CHINA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 149 CHINA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 150 CHINA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 151 CHINA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 152 CHINA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Rapidly increasing population and high incidence of infectious diseases to propel market growth
TABLE 153 INDIA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 154 INDIA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 155 INDIA LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 156 INDIA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 157 INDIA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.4.5 AUSTRALIA
10.4.5.1 Rising public-private investments and growing research on diagnostic applications to drive market
TABLE 158 AUSTRALIA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 159 AUSTRALIA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 160 AUSTRALIA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 161 AUSTRALIA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 162 AUSTRALIA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.4.6 SOUTH KOREA
10.4.6.1 Strong government support and increased adoption of advanced diagnostic technologies to aid market growth
TABLE 163 SOUTH KOREA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 164 SOUTH KOREA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 165 SOUTH KOREA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 166 SOUTH KOREA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 167 SOUTH KOREA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.4.7 REST OF ASIA PACIFIC
TABLE 168 REST OF ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 169 REST OF ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 REST OF ASIA PACIFIC: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 171 REST OF ASIA PACIFIC: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 172 REST OF ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.5 LATIN AMERICA
TABLE 173 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 174 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 175 LATIN AMERICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 176 LATIN AMERICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 177 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 178 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 179 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 180 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
10.5.1 LATIN AMERICA: RECESSION IMPACT
10.5.2 BRAZIL
10.5.2.1 High healthcare expenditure and presence of key manufacturers to support market growth
TABLE 181 BRAZIL: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 182 BRAZIL: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 183 BRAZIL: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 184 BRAZIL: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 185 BRAZIL: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.5.3 MEXICO
10.5.3.1 Supportive government initiatives and increased healthcare investments to augment market growth
TABLE 186 MEXICO: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 187 MEXICO: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 188 MEXICO: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 189 MEXICO: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 190 MEXICO: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.5.4 REST OF LATIN AMERICA
TABLE 191 REST OF LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 192 REST OF LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 193 REST OF LATIN AMERICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 194 REST OF LATIN AMERICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 195 REST OF LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
TABLE 196 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 197 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 198 MIDDLE EAST & AFRICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 199 MIDDLE EAST & AFRICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 200 MIDDLE EAST AND AFRICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 201 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022–2029 (USD MILLION)
TABLE 202 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 203 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022–2029(USD MILLION)
10.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
10.6.2 GCC COUNTRIES
10.6.2.1 High incidence of infectious diseases and technological advancements to fuel market growth
TABLE 204 GCC COUNTRIES: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 205 GCC COUNTRIES: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 206 GCC COUNTRIES: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 207 GCC COUNTRIES: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 208 GCC COUNTRIES: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
10.6.3 REST OF MIDDLE EAST & AFRICA
TABLE 209 REST OF MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022–2029(USD MILLION)
TABLE 210 REST OF MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 211 REST OF MIDDLE EAST & AFRICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 212 REST OF MIDDLE EAST & AFRICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 213 REST OF MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022–2029 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL MICROBIOLOGY MARKET
FIGURE 42 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
11.3 REVENUE ANALYSIS
FIGURE 43 REVENUE ANALYSIS FOR KEY PLAYERS IN CLINICAL MICROBIOLOGY MARKET (2021–2023)
11.4 MARKET SHARE ANALYSIS
FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CLINICAL MICROBIOLOGY MARKET (2023)
TABLE 214 CLINICAL MICROBIOLOGY MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 PERVASIVE PLAYERS
11.5.3 EMERGING LEADERS
11.5.4 PARTICIPANTS
FIGURE 45 CLINICAL MICROBIOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
FIGURE 46 CLINICAL MICROBIOLOGY MARKET: COMPANY FOOTPRINT
11.5.5.2 Product footprint
TABLE 215 CLINICAL MICROBIOLOGY MARKET: PRODUCT FOOTPRINT
11.5.5.3 Application footprint
TABLE 216 CLINICAL MICROBIOLOGY MARKET: APPLICATION FOOTPRINT
11.5.5.4 End user footprint
TABLE 217 CLINICAL MICROBIOLOGY MARKET: END USER FOOTPRINT
11.5.5.5 Region footprint
TABLE 218 CLINICAL MICROBIOLOGY MARKET: REGION FOOTPRINT
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 DYNAMIC COMPANIES
11.6.3 RESPONSIVE COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 47 CLINICAL MICROBIOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
TABLE 219 CLINICAL MICROBIOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 220 CLINICAL MICROBIOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
11.7 VALUATION & FINANCIAL METRICS
FIGURE 48 EV/EBITDA OF KEY VENDORS
FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
11.8 BRAND/PRODUCT COMPARISON
FIGURE 50 CLINICAL MICROBIOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES
TABLE 221 CLINICAL MICROBIOLOGY MARKET: PRODUCTS LAUNCHES,
JANUARY 2021–MAY 2024
11.9.2 DEALS
TABLE 222 CLINICAL MICROBIOLOGY MARKET: DEALS, JANUARY 2021–MAY 2024
11.9.3 OTHER DEVELOPMENTS
TABLE 223 CLINICAL MICROBIOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 BIOMЙRIEUX
TABLE 224 BIOMЙRIEUX: COMPANY OVERVIEW
FIGURE 51 BIOMЙRIEUX: COMPANY SNAPSHOT (2023)
TABLE 225 BIOMЙRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 226 BIOMЙRIEUX: DEALS, JANUARY 2021–MAY 2024
12.1.2 DANAHER CORPORATION
TABLE 227 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 52 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 228 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 229 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.3 BECTON, DICKINSON AND COMPANY
FIGURE 53 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
TABLE 231 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 232 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024
TABLE 233 BECKTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021–MAY 2024
TABLE 234 BECKTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.4 ABBOTT
FIGURE 54 ABBOTT: COMPANY SNAPSHOT (2023)
TABLE 236 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 237 ABBOTT: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.5 F. HOFFMANN-LA ROCHE LTD.
FIGURE 55 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
TABLE 239 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 240 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES,
JANUARY 2021–MAY 2024
TABLE 241 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–MAY 2024
TABLE 242 F. HOFFMAN-LA ROCHE LTD.: OTHER DEVELOPMENTS,
JANUARY 2021–MAY 2024
12.1.6 THERMO FISHER SCIENTIFIC INC.
TABLE 243 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 56 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 244 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 245 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024
TABLE 246 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–MAY 2024
12.1.7 AGILENT TECHNOLOGIES, INC.
FIGURE 57 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 248 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 249 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021–MAY 2024
12.1.8 BRUKER
TABLE 250 BRUKER: COMPANY OVERVIEW
FIGURE 58 BRUKER: COMPANY SNAPSHOT (2022)
TABLE 251 BRUKER: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 252 BRUKER: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024
TABLE 253 BRUKER: DEALS, JANUARY 2021–MAY 2024
12.1.9 HOLOGIC, INC.
TABLE 254 HOLOGIC, INC.: COMPANY OVERVIEW
FIGURE 59 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
TABLE 255 HOLOGIC, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 256 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024
TABLE 257 HOLOGIC, INC.: DEALS, JANUARY 2021–MAY 2024
12.1.10 MERCK KGAA
TABLE 258 MERCK KGAA: COMPANY OVERVIEW
FIGURE 60 MERCK KGAA: COMPANY SNAPSHOT (2022)
TABLE 259 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 260 MERCK KGAA: DEALS, JANUARY 2021–MAY 2024
TABLE 261 MERCK KGAA: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.11 BIO-RAD LABORATORIES, INC.
TABLE 262 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
FIGURE 61 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 263 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 264 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021–MAY 2024
TABLE 265 BIO-RAD LABORATORIES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
12.1.12 QIAGEN
TABLE 266 QIAGEN: COMPANY OVERVIEW
FIGURE 62 QIAGEN: COMPANY SNAPSHOT (2023)
TABLE 267 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 268 QIAGEN: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024
TABLE 269 QIAGEN: DEALS, JANUARY 2021–MAY 2024
12.1.13 SHIMADZU CORPORATION
TABLE 270 SHIMADZU CORPORATION: COMPANY OVERVIEW
FIGURE 63 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 271 SHIMADZU CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.14 NEOGEN CORPORATION
TABLE 272 NEOGEN CORPORATION: COMPANY OVERVIEW
FIGURE 64 NEOGEN CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 273 NEOGEN CORPORATION: PRODUCTS/ SERVICES/SOLUTIONS OFFERED
TABLE 274 NEOGEN CORPORATION: DEALS, JANUARY 2021–MAY 2024
12.1.15 SIEMENS HEALTHINEERS AG
TABLE 275 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
FIGURE 65 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
TABLE 276 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.16 HARDY DIAGNOSTICS
TABLE 277 HARDY DIAGNOSTICS: COMPANY OVERVIEW
TABLE 278 HARDY DIAGNOSTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.17 EMSL ANALYTICAL, INC.
TABLE 279 EMSL ANALYTICAL, INC.: COMPANY OVERVIEW
TABLE 280 EMSL ANALYTICAL, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.18 LIOFILCHEM SRL
TABLE 281 LIOFILCHEM SRL: COMPANY OVERVIEW
TABLE 282 LIOFILCHEM SRL: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.19 TCS BIOSCIENCES
TABLE 283 TCS BIOSCIENCES: COMPANY OVERVIEW
TABLE 284 TCS BIOSCIENCES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
12.1.20 COLE-PARMER INSTRUMENT COMPANY, LLC
TABLE 285 COLE-PARMER INSTRUMENT COMPANY, LLC: COMPANY OVERVIEW
TABLE 286 COLE-PARMER INSTRUMENT COMPANY, LLC: PRODUCTS/SERVICES/ SOLUTIONS OFFERED
12.2 OTHER PLAYERS
12.2.1 MEMMERT GMBH + CO.KG
TABLE 287 MEMMERT GMBH + CO.KG COMPANY OVERVIEW
12.2.2 VACUTEST KIMA S.R.L
TABLE 288 VACUTEST KIMA S.R.L.: COMPANY OVERVIEW
12.2.3 RAPID MICRO BIOSYSTEMS, INC.
TABLE 289 RAPID MICRO BIOSYSTEMS, INC..: COMPANY OVERVIEW
12.2.4 BIOTECHNOLOGY SOLUTIONS TX, LLC
TABLE 290 RAPID MICRO BIOSYSTEMS, INC.: COMPANY OVERVIEW
12.2.5 ARROW DIAGNOSTICS
TABLE 291 ARROW DIAGNOSTICS: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
